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Abstract
Background: In recent decades, low-level laser therapy (LLLT) has been widely used to relieve pain caused by different
musculoskeletal disorders. Though widely used, its reported therapeutic outcomes are varied and conflicting. Results
similarly conflict regarding its usage in patients with nonspecific chronic low back pain (NSCLBP). This study investigated
the efficacy of low-level laser therapy (LLLT) for the treatment of NSCLBP by a systematic literature search with
meta-analyses on selected studies.
Method: MEDLINE, EMBASE, ISI Web of Science and Cochrane Library were systematically searched from January
2000 to November 2014. Included studies were randomized controlled trials (RCTs) written in English that compared LLLT
with placebo treatment in NSCLBP patients. The efficacy effect size was estimated by the weighted mean
difference (WMD). Standard random-effects meta-analysis was used, and inconsistency was evaluated by the
I-squared index (I2).
Results: Of 221 studies, seven RCTs (one triple-blind, four double-blind, one single-blind, one not mentioning
blinding, totaling 394 patients) met the criteria for inclusion. Based on five studies, the WMD in visual analog
scale (VAS) pain outcome score after treatment was significantly lower in the LLLT group compared with placebo
(WMD= -13.57 [95 % CI = -17.42, -9.72], I2 = 0 %). No significant treatment effect was identified for disability scores or
spinal range of motion outcomes.
Conclusions: Our findings indicate that LLLT is an effective method for relieving pain in NSCLBP patients. However,
there is still a lack of evidence supporting its effect on function.
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Background
Low back pain (LBP) is one of the most common mus-
culoskeletal disorders [1, 2] and the leading cause of dis-
ability worldwide [3]. It affects more than two-thirds of
the population during their lifetime and one in four
people seek medical help for LBP in a 6-month period
[4]. Musculoskeletal disorders account for 6–8 % of total
disability-adjusted life years (DALYs) and of this large
total, low back pain accounts for nearly half [5]. The ma-
jority of the symptoms resolve spontaneously within 1–3
months. However, 3–10 % of patients develop chronic
symptoms lasting more than 6 weeks [6]. The underlying
etiology of most low back pain is currently unclear.
Thus, the one term, nonspecific chronic low back pain
(NSCLBP), is used to refer to this condition [7]. Annu-
ally, $91 billion in medical expenses are spent for back
pain with an additional $50 billion indirect costs in-
curred due to loss in productivity and disability benefit
payments [8, 9].
The main goal of NSCLBP therapy is rarely the
complete eradication of pain. Different strategies are
currently utilized including surgery and drug therapy,
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exercise therapy, manipulation, acupuncture, electrical
treatments, and cognitive-behavioral interventions.
In recent decades, low-level laser therapy (LLLT) has
been widely used to relieve pain caused by different
musculoskeletal disorders [10, 11]. Though widely used,
its reported therapeutic outcomes are varied and con-
flicting. Results similarly conflict regarding its usage in
patients with NSCLBP [12, 13]. There has been a recent
increase in the number of RCTs evaluating the effective-
ness of LLLT in patients with NSCLBP [12–18]. There-
fore, the aim of this study was to examine the totality of
evidence to evaluate the effectiveness of LLLT on symp-
toms and function in patients with NSCLBP through a
systematic review and meta-analysis.
Methods
Search strategy and study selection
We conducted a systematic review and meta-analysis,
using the approach recommended by the PRISMA (Pre-
ferred Reporting Items for Systematic Review and Meta-
Analyses) guidelines for meta-analyses of interventional
studies [19]. The following bibliographic databases were
searched up to 20 December 2014: Medline via PubMed
from 1990, EMBASE via OVID from 1990, Web of
Science from 1990 as well as the Cochrane Central
Register of Controlled Trials. The search strategy was as
follows: back pain OR low back pain OR backache OR
lumbar adjacent pain OR chronic low back pain OR
nonspecific chronic low back pain OR NSCLBP AND
low-level laser therapy OR low-intensity laser therapy
OR low-energy laser therapy OR LLLT OR LILT OR
LELT OR infrared laser OR IR laser OR diode laser.
Two reviewers independently identified titles and ab-
stracts relevant to LLLT for patients suffering from
NSCLBP. Full texts of the published articles were ana-
lyzed and included. The reference list of the full-text ar-
ticles was also reviewed. To be included in this analysis,
studies had to meet the following criteria: (1) be ran-
domized controlled trials; (2) involve patients suffering
from NSCLBP; (3) compare LLLT and placebo treatment
(no treatment or sham laser); (4) report pain and/or
functional outcomes of patients; (5) attain a PEDro score
(an 11-point scale, which is the one most often
employed for physical treatments) [20] of >5 and (6) be
written in English. Trials with an unbalanced additional
modality between groups were excluded.
Data extraction
Study data were extracted by two reviewers and checked
for accuracy by a third reviewer including the interven-
tion description, inclusion/exclusion criteria, baseline,
demographics, and values for all outcomes at baseline
and after treatment. The primary outcomes of interest
were the visual analog pain (VAS) pain score and
disability measured by the Oswestry disability index
(ODI) [21] after treatment. The secondary outcomes of
interest were change in VAS pain score (defined as the
mean difference between treatment arms from baseline
to follow-up) and range of motion (ROM). If the data
were not presented in the study as mean and standard
deviation, or were presented in a form that prevented
calculation of mean and standard deviation, the original
authors were contacted.
Statistical analysis
All the primary and secondary outcomes were continu-
ous data, permitting means and standard deviations to
be used to calculate a weighted mean difference (WMD)
and 95 % confidence interval (CI) in the meta-analysis.
Data were presented as a forest plot. All results were
checked for clinical and statistical heterogeneity. Hetero-
geneity was evaluated by a test for heterogeneity (I2 stat-
istic): significant heterogeneity was defined as I2 ≤ 0.10;
substantial heterogeneity was defined as I2 > 50 %. Data
were pooled using a random-effects model. All analyses
were conducted using Stata software, version 11.0 (Stata
Inc., College Station, TX, USA).
Results
Study selection and characteristics
Figure 1 illustrates the selection process for including
studies in the meta-analysis. In total, 221 potential stud-
ies were found. Based on the title and abstract content,
202 of these studies were excluded. The full texts of the
remaining 19 studies were read, and a further 12 studies
were excluded, resulting in seven studies [12–18]
retained in the qualitative and quantitative synthesis of
this review. A total of 394 patients were included: 202
patients in the LLLT group and 192 patients in the pla-
cebo group. Among the total of seven studies, three
[16–18] included exercise as an additional treatment
method in both study and control groups, while the
other four did not. The characteristics of the included
studies are listed in Table 1. Six of the seven studies
achieved a high-quality PEDro score (≥7) (Table 2). Two
otherwise relevant trials were excluded due to PEDro
scores < =5. All outcomes with appropriately reported
data were extracted and included in the meta-analysis.
Outcome measures were grouped according to their
construct and design (Table 3).
Meta-analysis
Pain relief
The mean VAS pain score after treatment was lower in the
LLLT compared with the placebo group (WMD= -13.57
[95 % CI = -17.42, -9.72], I2 = 0 %). Subgroup analysis
showed that exercise as an additional treatment did not
change the results (Fig. 2). Three [12, 17, 18] of the
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included studies provided data on change in short-term
VAS pain (follow-up minus baseline). The meta-analysis re-
vealed significantly greater decline in VAS pain in response
to LLLT compared with placebo treatment (WMD= -12.00
[95 % CI = -2.02, -21.98] I2 = 77.6 %) (Table 4).
Disability score
Disability data measured by ODI after treatment were
provided by four studies [13, 15–17]. The ODI measures
intensity of pain, lifting and activities such as ability to
care for oneself, ability to walk, ability to sit, sexual
function, ability to stand, social life, sleep quality and
ability to travel. The combined results showed no sig-
nificant difference between LLLT and placebo groups
(WMD= -2.89 [95 % CI = -7.88, 2.29], I2 = 88 %) (Fig. 3).
ROM
Data on ROM after treatment were provided by three
studies and included flexion (angle measured in de-
grees), anterior-posterior flexion (measured in centime-
ters) and extension (angle measured in degrees). The
combined data in terms of these three parameters
demonstrated no statistical difference between the treat-
ment groups (Table 4).
Discussion
NSCLBP is defined as pain of the lumbosacral area of
the spine lasting more than 12 weeks. NSCLBP is a com-
plex and multifactorial condition that may or may not
have the characteristic of limiting the patient’s ROM [6].
Though various treatments options have been proposed,
the management is still controversial. Most patients with
NSCLBP who require medication for pain relief are
likely to be middle-aged or older, and are at high risk for
both adverse gastrointestinal and cardiovascular side ef-
fects [22]. Also the long-term surgical outcomes are no
better than medical management [23]. Since first intro-
duced by Mester et al. in 1968 [24], clinical application
of LLLT has become more and more popular. Several
experimental and clinical studies [25, 26] demonstrated
its effectiveness for relief of chronic pain. Thus, many
patients seek LLLT because it has no accompanying det-
rimental effects on systemic cardiovascular health or
other adverse effects. Recently, several high-quality RCTs
Fig. 1 CONSORT diagram showing screening process and search results for the meta-analysis of LLLT for chronic nonspecific low back pain. LLLT
low-level laser therapy
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have emerged to assess the effectiveness of LLLT in pa-
tients with NSCLBP. We performed the current analysis,
including seven RCTs with 394 patients, to gain a better
understanding of the overall effect of LLLT for NSCLBP
based on the higher-quality studies in a field full of
seemingly conflicting results. Overall the analysis sug-
gests that: (1) LLLT can relieve NSCLBP in a manner su-
perior to placebo treatment; (2) LLLT is not superior to
placebo treatment with respect to disability or ROM
outcomes.
The mechanisms for LLLT-mediated pain relief are
not fully understood. Several possible mechanisms are
believed to account for the effects of LLLT, such as the
following: (a) increased endogenous opioid neurotrans-
mitter production [27]; (b) raised threshold to thermal
pain and enhanced local blood circulation [28]; (c) in-
creased oxygen consumption by accelerating the redox
reaction rate of the electron respiratory chain of
mitochondria [29]; (d) increased adenosine triphosphate
(ATP) production at the cellular level [30]; (e) increased
production of anti-inflammatory cytokines [12].
Multiple variables affect the clinical therapeutic ef-
fects of laser therapy, such as wavelength, energy dens-
ity, the number of treatment sessions and their
duration [31, 32]. Wavelength is also considered an es-
sential parameter for beneficial outcomes of LLLT; it
determines the ability of a laser to penetrate tissue.
Wavelengths in a range of 700–1000 nm are most often
used to treat deep tissues because of their superior
penetration [33]. The recommended LLLT wavelengths
per World Association of Laser Therapy (WALT)
guidelines are 780–860 nm [34] and 904 nm [35] de-
pending upon the condition being treated. Previous
studies [36, 37] have also reported better therapeutic
effects of LLLT with higher energy density, number of
sessions and frequency of application. All the included
Table 2 Summary of methodological quality based on PEDro classification scale
Study Item Total
1 2 3 4 5 6 7 8 9 10 11
Klein and Eek 1990 [13] ✓ ✓ x ✓ ✓ ✓ ✓ ✓ x ✓ ✓ 9
Soriano and Rios 1998 [14] ✓ ✓ x ✓ x x x ✓ x ✓ ✓ 6
Basford et al. 1999 [15] ✓ ✓ x ✓ ✓ ✓ x ✓ x ✓ ✓ 8
Gur et al. 2003 [16] ✓ ✓ x ✓ ✓ x x ✓ x ✓ ✓ 7
Djavid et al. 2007 [17] ✓ ✓ x ✓ ✓ ✓ x ✓ x ✓ ✓ 8
Vallone et al. 2014 [18] ✓ ✓ ✓ ✓ x x x ✓ x ✓ ✓ 7
Hsieh et al. 2014 [12] ✓ ✓ ✓ ✓ ✓ x ✓ ✓ x ✓ ✓ 9
Items: 1-eligibility criteria specified, 2-random allocation, 3-concealed allocation, 4-groups similar at baseline, 5-subject blinding, 6-therapist blinding, 7-assessor
blinding, 8-less than 15 % dropouts, 9-intention-to-treat analysis, 10-between-group statistical comparisons, 11-point measures and variability data; ✓yes, x no
Table 1 General information on low-level laser therapy (LLLT) included in the meta-analysis
Study Type of studies Sample size Age (SD) years Gender (M/F) Dropouts (n) VAS pain (SD) Intervention
Klein and Eek 1990 [13] TB-RCT Study group (n = 10) 44.1 (7.9) 2/8 0 30 (12) LLLT vs. Placebo
Control group (n = 10) 41.3 (10.7) 3/8 0 33 (11)
Soriano and Rios 1998 [14] DB-RCT Study group (n = 38) 63.2 16/22 0 79 LLLT vs. Placebo
Control group (n = 33) 64.33 18/20 0 81
Basford et al. 1999 [15] DB-RCT Study group (n = 27) 47.8 (48.0) 18/12 3 35.2 (29.0) LLLT vs. Placebo
Control group (n = 29) 48.2 (49) 13/16 0 37.4 (36.0)
Gur et al. 2003 [16] SB-RCT Study group (n = 25) 35.2 (10.51) 7/18 0 62 (21) LLLT + Ex vs.
Placebo + Ex
Control group (n = 25) 36.4 (9.83) 8/17 0 65 (16)
Djavid et al. 2007 [17] DB-RCT Study group (n = 19) 38 (7) 12/7 0 62 (16) LLLT + Ex vs.
Placebo + Ex
Control group (n = 18) 36 (10) 15/3 0 63 (20)
Vallone et al. 2014 [18] RCT Study group (n = 50) 68 (24-89) 43/57 0 66.4 (17.7) LLLT + Ex vs.
Placebo + Ex
Control group (n = 50) 0 63.6 (15.2)
Hsieh et al. 2014 [12] DB-RCT Study group (n = 33) 60.1 (14.2) 14/19 0 78 (24) LLLT vs. Placebo
Control group (n = 27) 58.5 (10.6) 8/19 0 79 (17)
Mean (standard deviation) are provided above for age (years) and VAS pain (VAS visual analog scale)
TB-RCT triple blind-randomized controlled trial, DB-RCT double-blind randomized controlled trial, SB-RCT single-bind randomized controlled trial, M male, F female,
Ex exercise
Huang et al. Arthritis Research & Therapy  (2015) 17:360 Page 4 of 8
studies used a wavelength within the recommended
range.
It is well recognized that the effects of phototherapy
are time-dependent [38]. We also observed this
phenomenon as demonstrated in this meta-analysis by
significant short-term but not moderate-term benefit. In
contrast to pain outcomes, we did not find any signifi-
cant improvement in disability or ROM due to LLLT.
There might be several reasons for this. For one, the
cause of NSCLBP is still unclear. Usually it is hard to de-
termine the precise etiology of the pain. Some theories
suggest that NSCLBP is linked to a reflex response of
the back extensor muscles, resulting in a loss of flexion
relaxation of the back muscles and a reduction of spinal
flexion with secondary increased tissue strain [39]. LLLT
may relieve the pain by increasing oxygen consumption
and blood supply to the muscles [40]. With respect to
duration, the effect is comparable to other interventions
(e.g., antidepressants and traction), which are effective in
the short term [41]. A primary effect on muscle may ex-
plain why we did not find any significant effect of LLLT
on knee osteoarthritis (OA) pain [42], in which the
sources of pain are diverse. Moreover, NSCLPB is likely
a heterogeneous group of diseases, which have different
etiologies but share similar symptoms. Thus, some of
them might react well to LLLT while others not. Only
two studies provided data on ROM. For this outcome,
negative results might relate to inadequate study power
that could be overcome with more high-quality investi-
gations with ROM. Finally, like other LBP interventions,
effects on pain appear to be stronger than effects on
function [43].
Seven years ago, Yousefi-Nooraie et al. [44] conducted
a meta-analysis of LLLT for nonspecific low back pain
(NLBP); it contained seven studies of both acute and
chronic NLBP [13–17, 45, 46]. The authors concluded
Table 3 Technical features of laser use in the studies included for meta-analysis









Energy per point (J/
point per session)
Klein and Eek 1990 [13] GaAs 904 nm Omniprobe 20 m/12/3 20 W 1.3 1.3
Soriano and Rios 1998 [14] GaAs 904 nm NA NA/10/5 40 mW 4 6*10-6
Basford et al. 1999 [15] Nd: YAG 1060 nm NA 12 m/12/3 542 mW 239.3 48.78
Gur et al. 2003 [16] GaAs 904 nm Class IIIb Laser
Product
30 m/20/5 4.2 mW 1 1
Djavid et al. 2007 [17] GaAlAs 810 nm NA 20 m/12/2 50 mW 27 5.9697
Vallone et al. 2014 [18] GaAlAs 980 nm LEONARDO BIO 6 m/9/3 20 W 37.5 1200
Hsieh et al. 2014 [12] GaAlAs 890 nm Anodyne 40 m/6/3 780 mW 10.4 NA
NA not available
Fig. 2 Forest plot analysis of the VAS pain score after LLLT treatment. WMD weighted mean difference, LLLT low-level laser therapy, VAS visual
analog scale; weight % stands for the portion of the total sample contributed by each study
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that data were insufficient to confirm the clinical effect-
iveness of LLLT for NLBP. Our study is more specific,
focusing on NCLBP, and is an update on this topic now
demonstrating the likelihood of a beneficial effect of
LLLT on low back pain. The difference in conclusions
can likely be attributed to several strengths of our study.
First, we focused on chronic LBP studies. The separation
of chronic from acute NLBP is likely to decrease the het-
erogeneity. Second, the power of the current meta-
analysis was substantially increased due to the inclusion
of two additional studies corresponding to an appre-
ciable increase in the numbers of subjects (sample size
increased two times) over the prior meta-analysis. What
is more, two low-quality studies were excluded due to
PEDro scores <5 [44, 45]. Even if we included the results
of theses two trials, the pooled results were still consist-
ent with results of analyses of the trials of higher quality.
Third, this meta-analysis was performed on the basis of
the Cochrane Collaboration’s principle and designed to
be rigorous in its search strategy. Fourth, narrow CIs
around the point estimates due to the availability of
higher-quality trials resulted in more precise estimates
of treatment effects.
Some limitations of the current meta-analysis warrant
discussion. First and foremost, we were limited by the
outcome reporting of the included studies; for instance,
only two studies were available for pooling to evaluate
ROM. Second, because of the relatively heterogeneous
treatment protocols with respect to laser parameters and
laser schedules, high heterogeneity was detected in sev-
eral outcomes. To overcome this, a random-effects
model was chosen. Third, three of the included studies
used exercise as an additional treatment in both study
and control groups, while the other four did not. This
could contribute to high heterogeneity in pooled results.
However, the subgroup analysis showed that the use of
adjunctive exercise did not affect the results. Fourth,
LLLT has been also extensively used and studied in Eur-
ope and Russia; by restricting to English language stud-
ies, we could have missed some trials. Fifth, due to our
relatively small number of trials, we could not assess
publication bias using funnel plots or statistical tests for
small sample effects.
Conclusions
The results of our systematic review and meta-analysis
have provided the best current evidence on LLLT for the
treatment of NSCLBP. It suggests that LLLT is an effect-
ive method to relieve low back pain in patients who
present with NSCLBP. However, there is still a lack of
Table 4 Meta-analyses of weighted mean differences in various continuous parameters between the LLLT and placebo groups
Outcome parameters* Number of patients Weighted mean
difference (95 % CI)
p value I2
LLLT group (n) Placebo group (n)
Change in VAS pain score after treatment
(from baseline to after treatment) 12,17,18
102 95 -12.00 [-2.02, -21.98] 0.012 77.6 %
Anterior-posterior flexion (degree)13,17 29 28 3.20 [-2.54, 8.93] 0.961 0 %
Anterior-posterior flexion (cm)15,16 35 35 -.2.84 [-5.44, 0.02] 0.480 0 %
Extension (degree)13,17 29 28 0.08 [-2.39, 2.54] 0.973 0 %
LLLT low-level laser therapy, VAS visual analog scale
*Study references provided by superscripts
Fig. 3 Forest plot analysis of disability outcomes after LLLT treatment measured by Oswestry disability index (ODI). LLLT low-level laser therapy
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evidence supporting its effectiveness on functional out-
comes. Further research is needed to identify the optimal
LLLT parameters for achieving therapeutic efficacy, par-
ticularly for functional outcomes, and for understanding
its mechanisms of action.
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